Rhode Island Hospital

Rhode Island Hospital, a Lifespan-partner

Roger Williams General Hospital

Other

Carter Wallace, Inc.

Geistlich Phama Ag

James W Darnowski

Paul Calabresi

James C Costin

Michael C Wiemann

Bai-Chuan Pan

The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.

Use of taurolidine to treat tumors

Methods of treating tumors

The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing methylol-containing compound. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.

Use of a methylol-containing compound to treat tumors

The invention provides antineoplastic composition containing an inhibitor of angiogenesis and an inhibitor of DNA topoisomerase type I enzyme activity.

Combination drug therapy

The invention provides a method of inhibiting tumor growth by contacting the tumor with a composition containing a taurine compound. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death.

Taurine compounds

Methods of treating tumors with taurolidine

Combinations of 3&prime;-azido-3&prime;-deoxythymidine (AZT) with 5-fluorouracil (FUra) or its precursor 5-fluoro-2&prime;-deoxyuridine (FUDR) or methoxtrexate (MTX) exhibit increased cytotoxicity and increased therapeutic index in treatment of carcinomas.

Drug cominbations containing AZT

Combinations of 3'-azido-3'-deoxythymidine (AZT) with 5-fluorouracil (FUra) or its precursor 5-fluoro-2'-deoxyuridine (FUDR) or methoxtrexate (MTX) exhibit increased cytotoxicity and increased therapeutic index in treatment of carcinomas.

Drug combinations containing AZT

The invention is directed to a method of inhibiting anemia caused by the administration of AZT to a patient which comprises administering to said patient an effective anemia-inhibiting amount of a combination of dipyridamole and 5-benzylacyclouridine. The invention is further directed to a pharmaceutical composition comprising as the active pharmaceutical agent a combination of dipyridamole and 5-benzylacyclouridine in association with a pharmaceutically acceptable carrier or diluent.

Growing community of inventors

Barrington, RI, United States of America

James W Darnowski